FEB 27, 2019 12:00 PM PST

Studies on Malignancies With a Novel Proliferation Biomarker

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Business Development Manager at AroCell AB
    Biography
      Martin Shaw has been involved in the development, production and promotion of novel biomarker and laboratory diagnostics for many years.

      His particular interest is using his technical and scientific skills and knowledge to link research to the customer's needs.

      In the field of laboratory diagnostics, he has been involved in the development and promotion of several ground-breaking products including the first commercial assays for neonatal TSH, anti-gliadin IgA and a range of inflammatory biomarkers.

      In the drug discovery industry, Martin has worked widely with novel cell and tissue injury biomarkers and their application to toxicology and drug discovery.

      Martin has participated in industry-wide consortia on the qualification on biomarkers for use in preclinical toxicology studies and phase I clinical trials

      Martin has published several review articles on the application of biomarkers in drug discovery and he has lectured at many conferences, including twice being guest speaker at the FDA.

      Currently he is working with a novel exciting biomarker of cell proliferation - The AroCell TK 210 ELISA kit that has great potential as a biomarker of cell proliferation in preclinical drug development and clinical trials.

    Abstract:

    Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassay

    There are many tumor biomarkers but, they mostly reflect tumor mass or past growth, when what may be more important would be to obtain an indication of future growth and therapy response.

    Proliferation biomarkers e.g. KI67, are mostly immunohistological biomarkers which are labor intensive, subjective and only show a small part of the tumor. The ability to measure a proliferation biomarker in an easily available body fluid could reduce this problem and provide new opportunities for studying tumor growth and therapy response. 

    Thymidine Kinase 1 (TK1) has the potential to be such as biomarker. 

    This presentation will demonstrate how the immunoassay of TK1, using a unique monoclonal antibody directed against the TK 210 epitope (AroCell TK 210 ELISA) can provide new opportunities for the study of tumor growth, therapy response and in-vitro modelling of drug effects.

    Thymidine Kinase 1 (TK1) is a key enzyme in DNA synthesis and it is up-regulated in the S phase of cell growth. It is released into the extracellular medium and, eventually, the blood during cell turnover.

    TK1 enzyme activity has been used for many years as a biomarker for hematological malignancies but the complexity of the assay, plus the fact that much of serum TK1 is inactive has restricted its use, particularly for solid tumors. However, all TK1 forms express the TK 210 epitope.

    In studies on hematological malignancies, the AroCell TK 210 ELISA provides similar information to that of the established enzyme activity assays but in studies on solid tumors, where much of the TK1 is enzymatically inactive, the AroCell TK1 ELISA is more sensitive, without losing specificity.

    The AroCell TK 210 ELISA kit can be profitably combined with biomarkers of tissue mass, e.g. CA15-3 increasing diagnostic accuracy.

    In in-vitro studies on the effects of anti-cancer drugs, the induction and release of TK1 following drug exposure are similar to those seen in-vivo making the assay of TK1 with the AroCell TK 210 ELISA kit a potentially valuable translational biomarker.

    Learning Objectives: 

    1. Most current tumor biomarkers provide a linked to tumor mass and/or cell death and are backward looking (past growth).
    2. When planning future therapy and making prognoses, biomarkers of current cell growth (proliferation biomarkers) can add valuable additional information.
    3. The immunoassay of Thymidine Kinase 1 can be such a biomarker


    Show Resources
    You May Also Like
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 14, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 14, 2019 09:00 AM PDT
    DATE: August 14, 2019TIME: 9:00am PT. 12:00pm ET Implementation of Lean Methodology in Biobanking Operations to standardize sample management processes is effective. Each proce...
    Loading Comments...
    Show Resources